Cabergoline, dopamine D2 receptor agonist, prevents neuronal cell death under oxidative stress via reducing excitotoxicity. [PDF]
PLoS ONE, 2014 Several lines of evidence demonstrate that oxidative stress is involved in the pathogenesis of neurodegenerative diseases, including Parkinson's disease. Potent antioxidants may therefore be effective in the treatment of such diseases.
Haruki Odaka +7 more
doaj +3 more sources
Long-Term Results of Cabergoline Add-on Long-Acting Somatostatin Analogue Therapy in Acromegaly Patients [PDF]
Gazi Medical JournalObjective: To investigate the efficacy of the dopamine agonist cabergoline in uncontrolled acromegaly despite long-acting somatostatin analog (SSA). Methods: Thirty-five patients with acromegaly who were followed up in the department of endocrinology ...
Mehmet Muhittin Yalçın +13 more
doaj +2 more sources
Successful Management of a Giant Pituitary Lactosomatotroph Adenoma Only with Cabergoline [PDF]
Case Reports in Endocrinology, 2013 Although advances in endocrinologic and neuroradiologic research allow easier recognition of pituitary adenomas, giant pituitary tumours are relatively rare.
Emre Bozkirli +5 more
doaj +2 more sources
Current Therapeutic Research, 2021 : Background: Although dopamine D2 receptor agonists, bromocriptine and cabergoline, are notable medications in the treatment of Parkinsonism, hyperprolactinemia, and hyperglycemia, there is an identified relationship between the utilization of D2-like ...
Mohammed Fouad Shalaby, MD +5 more
doaj +2 more sources
Indian Journal of Endocrinology and Metabolism, 2021 Cabergoline has long been used in the medical management of prolactin-secreting pituitary adenomas. However, there is contradicting and inadequate evidence on the efficacy of cabergoline in achieving radiological and biochemical remission in prolactinoma.
Rakesh Mishra +5 more
doaj +2 more sources
Comparative study of cabergoline and hydroxychloroquine to prevent ovarian hyperstimulation syndrome (OHSS) in PCOS patients: a pilot randomized clinical trial [PDF]
Journal of Ovarian ResearchBackground This study compared the effectiveness of cabergoline and hydroxychloroquine in preventing ovarian hyperstimulation syndrome (OHSS) in patients with polycystic ovary syndrome (PCOS) undergoing controlled ovarian stimulation.
Elnaz Salari +4 more
doaj +2 more sources
Higher doses of cabergoline further improve metabolic parameters in patients with prolactinoma regardless of the degree of reduction in prolactin levels. [PDF]
, 2013 OBJECTIVE: Currently available studies that fully analyse the metabolic parameters in patients with prolactinoma are scarce and discordant. The aim of this study was to evaluate the metabolic effects of cabergoline (CAB) treatment in patients with newly
AMATO, Marco Calogero +4 more
core +3 more sources
The Effects of Cabergoline Compared to Dienogest in Women with Symptomatic Endometrioma
Fertility & Reproduction, 2021 Background: New vessel formation or neovascularization has been recognized as a feature of endometriosis. Treatment with cabergoline suppresses cell proliferation and vascular-endothelial-growth-factor-mediated angiogenesis, thereby promoting regression ...
Mehnaz Mustary Shume +5 more
doaj +1 more source
Frontiers in Endocrinology, 2022 The mammalian target of rapamycin (mTOR) inhibitor everolimus has been shown to display antiproliferative effects on a wide spectrum of tumors. In vitro studies demonstrated that everolimus inhibited pituitary neuroendocrine tumor (PitNET) cell growth in
Federica Mangili +18 more
doaj +1 more source